Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
See all ideas
MRNAModerna looks ready to take on the world, with the efficacy of its new cancer vaccine turning heads.
MRNAVaccine stocks spiral as their efficacy against the Delta variant is called into question. Moderna takes the worst of it, down just under 16% to close at $385.33.
MRNAVaccine hero Moderna opens Monday up 6% and finishes the day with a 9.5% bump, building on its share price jump of 10% on Friday on news that the biotech leader is set to get a S&P 500 listing.
See all events
